何氏眼科上述负责人表示，此次中意眼健康创新合作专场活动的成功举办，是何氏眼科推动国际眼健康 合作的重要实践，也为中意科技合作惠及民生提供助力。未来，何氏眼科将锚定"智慧光明城"战略目 标，持续深化国际交流合作，推动眼健康技术创新与公益服务协同发展，推动眼健康事业高质量发展。 本次合作的意大利Adaptica公司致力于开发制造简单、便携、基于人工智能的移动眼科设备，主要用于 检测屈光不正和视觉缺陷。Adaptica公司整合优秀专家资源，经过多年的研发和市场实践，在眼科医疗 设备领域积累了丰富经验，技术水平处于同行业领先地位。 值得关注的是，何氏眼科在眼健康领域深耕30年，始终坚持立业为善，长期开展眼健康公益服务。在数 字化浪潮推动下，何氏眼科将技术创新与公益服务相结合，打造眼健康公益新生态，通过公益项目、医 生培训等方式服务群众。持续创新的"三级眼健康医疗服务模式"已成为可复制、可持续的公益医疗样 本，服务模式获行业认可。 中证报中证网讯（王珞）日前，中欧生物医药产业创新合作对接会——中意眼健康创新合作专场活动在 北京举办。本次活动由北京国际技术交易联盟（NICTC）和中关村企业驻意大利那不勒斯服务代表处主 办 ...

Core Insights - Beijing's small and medium-sized enterprises (SMEs) have shown significant progress in high-quality development, with the number of "little giant" enterprises increasing by over 1,000 [1][2] Group 1: SME Development - As of September 2024, there are 2.212 million active SMEs in Beijing, an increase of 133,000 compared to the same period last year, representing a year-on-year growth of 6.4% [2] - The number of newly established enterprises from January to September 2024 reached 235,000, a year-on-year increase of 22.3%, averaging over 850 new SMEs per day [2] - The number of specialized and innovative SMEs has increased more than tenfold since the beginning of the 14th Five-Year Plan, with over 12,000 national-level specialized "little giant" enterprises [2][3] Group 2: Economic Indicators - The SME development index for September 2024 was 98.7, reflecting a 3.8-point increase from the same month last year, with significant improvements in funding and employment indices [2] - Scale above SMEs in Beijing totaled 44,000, achieving a total profit of 329.48 billion yuan, a year-on-year increase of 13.5% [2] Group 3: Innovation and R&D - Specialized and innovative enterprises have an average R&D investment exceeding 18 million yuan, with about 40% focusing on future industries such as AI and genetic technology [3] - In the preliminary evaluation for the 2025 National Science and Technology Awards, 26 specialized and innovative enterprises participated in 24 projects, accounting for approximately 10% of the total national projects [3] Group 4: Financing and Investment - As of September 2024, there are 476 listed companies in Beijing, with 180 specialized and innovative enterprises, making up 37.8% of the total listed companies [3] - The balance of inclusive small and micro loans from financial institutions in Beijing reached 1.1 trillion yuan, a year-on-year increase of 12.3%, with the average interest rate for new loans at 3.99%, down 21 basis points year-on-year [3]

Group 1 - The event "China-Europe Biopharmaceutical Industry Innovation Cooperation Matchmaking Conference - China-Italy Eye Health Innovation Cooperation Special Session" was held in Beijing, organized by NICTC and the Naples service office of Zhongguancun Enterprises in Italy, with participation from various eye care and technology institutions from China and Italy [2] - He Eye Hospital, a technology-driven listed company, aims to create a comprehensive ecosystem for eye health, focusing on global innovation and serving the Chinese public [2][3] - The collaboration with Italian partners will focus on key areas such as refractive cataract, myopia prevention in youth, and dry eye treatment, promoting the transformation of international innovative technologies into products and clinical applications [2][3] Group 2 - Adaptica's Professor Ksenija Ili introduced a new product developed in collaboration with He Eye Hospital, which will provide public eye health services to youth and underdeveloped regions through AI screening devices [3] - He Eye Hospital has been dedicated to eye health for 30 years, combining technological innovation with public service to create a new ecosystem for eye health, recognized for its sustainable and replicable "three-tier eye health service model" [3] - The successful hosting of the China-Italy Eye Health Innovation Cooperation Special Session marks an important step for He Eye Hospital in promoting international eye health cooperation and contributing to the "Healthy China" initiative [3]

扬子晚报网11月14日讯(记者徐昇)11月14日，苏南片区知识产权保护高地建设新闻发布会在南京召开。据悉，江苏连续五年在 中央知识产权保护专项考核中获评优秀等次，2024年得分跃居全国首位，知识产权保护水平、知识产权保护全社会满意度均 位列全国第一，构建了全国唯一、覆盖全省的"1+13+N"知识产权快速协同保护体系，上海-苏州、南京两地共同跻身世界知识 产权组织发布的"全球百强创新集群"前15强，为江苏切实扛起"经济大省勇挑大梁"重大责任提供了有力的知识产权支撑。 近年来，江苏知识产权行政保护能力大幅提升。"十四五"期间，全省办理专利侵权纠纷案件达1.7万件，是"十三五"时期的近3 倍。全省积极推动"1+13+N"快速协同保护体系提质增效、统筹联动，扎实开展"双白名单"试点，充分发挥知识产权保护中 心"快速授权、快速确权、快速维权"的职能作用，高效服务创新。 涉外知识产权保护服务体系不断健全。江苏积极推动14个海外知识产权纠纷应对指导地方分中心由机构建设向功能发挥转 变，围绕企业更好"走出去"、出口转内销等加强前端服务，打造外贸产业、出口产品、海外商标、境外展会、跨境电商建 立"五位一体"的服务体系，建设省涉 ...

Core Insights - The establishment of the Sci-Tech Innovation Board (STAR Market) has significantly enhanced China's capital market's ability to support technological innovation, with 592 listed companies and total fundraising exceeding 1.1 trillion yuan by October 2025 [1][3] - The STAR Market has demonstrated strong growth, with a compound annual growth rate (CAGR) of 18% in revenue and 9% in net profit for listed companies over the past five years [3][4] - The board has successfully fostered a vibrant ecosystem for hard technology, with over 80% of companies in emerging industries such as new-generation information technology and biomedicine [4][5] Company Performance - As of 2025, 22 out of 57 unprofitable companies listed on the STAR Market have achieved profitability, indicating a positive trend in financial performance [3] - The integrated circuit sector has over 120 listed companies, with revenue and net profit growth of 27% and 83% respectively in the first three quarters of 2025 [4] - In the biopharmaceutical sector, 21 out of 22 companies have received approval for 48 drugs/vaccines, contributing significantly to the innovation landscape [4] R&D Investment - The total R&D investment by STAR Market companies reached 1,680 billion yuan in 2024, more than three times their net profit [5] - In the first three quarters of 2025, R&D investment amounted to 1,133.45 billion yuan, a year-on-year increase of 9.01% [5] - The average number of invention patents per company on the STAR Market is 230, with 30% of companies having products or projects that are industry-first [5][6] Ecosystem Development - The STAR Market has created a virtuous cycle of "technology-industry-capital," enhancing the efficient allocation of innovative resources [7] - Over 60% of the founding teams of STAR Market companies consist of scientists or industry experts, fostering a strong innovation culture [7] - The market has seen a significant increase in cash dividend proposals, with a total of 38.8 billion yuan in dividends planned for 2024 [8] Institutional Innovation - The STAR Market has pioneered various institutional innovations, including diverse listing standards and mechanisms for rapid financing, which serve as a model for other markets [9] - Recent reforms have expanded the scope of the STAR Market to include more cutting-edge fields, enhancing its inclusivity [9] - The growth of the STAR Market's "growth layer" has accelerated, with companies showing revenue growth of 35.09% and a median R&D intensity of 44.34% [9] Future Outlook - The Shanghai Stock Exchange aims to further leverage the STAR Market as a testing ground for identifying high-quality tech companies, particularly in emerging fields like artificial intelligence and aerospace [10]

Core Insights - The Science and Technology Innovation Board (STAR Market) has successfully gathered 592 listed companies by October 2025, with a cumulative IPO fundraising scale of 934.6 billion yuan and total financing exceeding 1.1 trillion yuan, becoming a key force in nurturing new productive forces and upgrading the modern industrial system [1][2] - Over the past five years, STAR Market companies have shown strong growth, with a compound annual growth rate of 18% in operating income and 9% in net profit attributable to shareholders, indicating robust growth potential [2][3] - The STAR Market has established a virtuous cycle ecosystem of "technology - industry - capital," effectively promoting the efficient allocation of innovative resources and attracting talent and investment [6][8] Group 1: Financial Performance - By October 2025, the STAR Market has raised a total of 934.6 billion yuan through IPOs, with total financing surpassing 1.1 trillion yuan [1] - The compound annual growth rates for operating income and net profit attributable to shareholders for STAR Market companies are 18% and 9%, respectively, since 2019 [2] - In the integrated circuit sector, 119 disclosed companies reported a revenue growth of 27% and a net profit growth of 83% year-on-year for the first three quarters of 2025 [3] Group 2: Industry Focus and Innovation - The STAR Market has maintained a focus on "hard technology," with over 80% of listed companies in emerging industries such as new-generation information technology, biomedicine, and high-end equipment manufacturing [3] - The STAR Market has seen significant advancements in key technologies, with companies like He Yuan Bio and Guo Dun Quantum achieving breakthroughs in innovative drugs and semiconductor technologies [4] - As of 2025, STAR Market companies have formed over 130,000 invention patents, with an average of 230 patents per company, showcasing a strong emphasis on innovation [4][5] Group 3: Ecosystem and Market Dynamics - The STAR Market has successfully attracted over 60% of its founding teams from scientific and engineering backgrounds, fostering a culture of innovation [6] - Approximately 90% of STAR Market companies received venture capital investment before going public, indicating strong investor confidence [6] - The STAR Market has developed a comprehensive index system with 33 indices, and the total scale of STAR Market-related index tracking products exceeds 330 billion yuan [6][7] Group 4: Regulatory and Institutional Innovations - The STAR Market has pioneered various institutional innovations, including multi-dimensional listing standards and a small-scale rapid financing mechanism, providing valuable lessons for other market segments [8] - Recent reforms, such as the "1+6" initiative, have further enhanced the inclusivity of the STAR Market, allowing for the expansion of standards to cover cutting-edge fields like artificial intelligence [8] - The Shanghai Stock Exchange aims to leverage the STAR Market's role as a "testing ground" to better identify high-quality technology enterprises and support their listing [9]

Core Viewpoint - The first China (International) Robot Debate Competition is showcasing the capabilities of robots in argumentation, highlighting advancements in AI and its implications for various sectors, including business and law [1][9]. Group 1: Competition Overview - The competition features 10 teams from universities and companies, engaging in debates on topics such as the appropriateness of AI monitoring employee efficiency [1]. - The event is taking place in Beijing's Yizhuang area, emphasizing the integration of AI in human activities [1]. Group 2: Robot Performance - The robot "Sirius" from Hubei University demonstrated improved debate skills, with enhanced response speed and accuracy in summarizing arguments [3]. - Robots are noted for their ability to remain unaffected by emotional pressure, maintaining composure throughout the debate [5]. Group 3: Technical Challenges - Issues such as speech recognition inaccuracies due to environmental factors were observed, indicating areas for future improvement in AI training datasets [3]. - Robots displayed strong logical reasoning and response capabilities, although they occasionally faced challenges in maintaining coherent speech during debates [7]. Group 4: Future Implications - The competition serves as a scientific experiment to test AI technology and its integration into humanities and social sciences [9]. - Future events will focus on practical applications of robots in sectors like hotel services and healthcare, aiming to accelerate the development of the robotics industry [10].

Core Insights - Cell and gene technology is becoming a crucial area of innovation in biomedicine, offering new possibilities for human health, but its development is constrained by policy direction, financing environment, and ethical norms [1][4] - Mario Capecchi, a Nobel laureate, emphasizes the foundational role of genes in biological research while acknowledging the significant influence of environmental factors [1][4] - Capecchi praises China's leading achievements in gene therapy and highlights the government's strong support for scientific research, contrasting it with the declining scientific enthusiasm in the U.S. due to policy changes [4][5] Group 1: Scientific Exploration and Challenges - Capecchi encourages researchers to contribute to future advancements, stressing the importance of overcoming challenges in scientific exploration, particularly in gene modification [2][6] - He notes that scientific research is a continuous process that often involves failure, and researchers must learn to coexist with change and setbacks [6][7] - Capecchi believes that the significance of data in research is sometimes overstated, advocating for practical assessments of experimental outcomes rather than relying solely on complex data analysis [6][7] Group 2: Market and Economic Aspects - The global cell and gene therapy market was valued at $5.8 billion in 2022 and is projected to grow to $23.33 billion by 2028, with a compound annual growth rate (CAGR) of 26.4% [7] - In China, the CGT market reached approximately 3.38 billion yuan in 2023, a 113.64% increase from the previous year, with expectations to grow to 8.84 billion yuan in 2024 and 18.63 billion yuan in 2025 [7] - Capecchi highlights the importance of reducing drug prices to ensure accessibility for patients, noting that market competition will drive down costs as demand increases [6][7]

Group 1 - The issuance of the "Intellectual Property Power Construction Outline (2021-2035)" marks a significant strategic design for the future development of intellectual property in China, emphasizing the importance of building a strong intellectual property nation [1][2] - China's ranking in the Global Innovation Index has improved from 35th in 2013 to 12th in 2021, indicating its rapid progress and solid foundation for becoming a strong intellectual property nation [2] - The construction of a strong intellectual property nation is essential for modernizing the national governance system, promoting high-quality development, and enhancing the overall competitiveness of the economy [3][4] Group 2 - The Outline sets forth the overall requirements for building a strong intellectual property nation, emphasizing the need for adherence to Xi Jinping's thoughts and the importance of strengthening intellectual property protection [5] - The development goals include achieving significant results by 2025, with stricter protection and higher social satisfaction, and establishing a strong intellectual property nation by 2035 [6] - Key tasks for implementing the Outline include establishing a comprehensive intellectual property legal system, creating a supportive environment for international business, and enhancing public services related to intellectual property [7][8]

Core Viewpoint - The company is focusing on a dual-platform development strategy of "Fine Chemicals + Precision Medicine," with the fine chemicals segment as the foundation and precision medicine as a new growth engine, aiming for long-term growth support [2]. Group 1: Company Performance and Strategy - The company reported a stock price of 18.96 yuan, up 3.44% with a trading volume of 144,900 shares and a turnover of 271 million yuan as of September 5, 2025 [1]. - The precision medicine segment has not yet achieved profitability, but there is a clear trend of reduced losses, with future plans to focus on cell therapy and gene technology [2]. - The company is collaborating with its investee companies, such as Huada Bio and Yongtai Bio, to integrate technology and resources, accelerating the transformation of research results into profit [2]. Group 2: Product Development and Market Position - Yongtai Bio's EAL (activated lymphocytes) injection has received acceptance for conditional listing application by the National Medical Products Administration, currently in the normal approval process [2]. - The company’s PVP (Polyvinylpyrrolidone) annual production capacity is approximately 20,000 tons, with applications in new energy (15%), medicine (35%), food (10%), and other industrial and cosmetic fields (40%) [2]. - PVP prices have stabilized after a significant drop compared to previous years, and the company expects an increase in average prices as the product structure upgrades and the proportion of high-end products rises [2][3]. Group 3: Financial Insights - The company's operating costs increased by 11.41% year-on-year to 367.23 million yuan, primarily due to increased sales volume [2]. - On September 5, 2025, the net outflow of main funds was 12.51 million yuan, while retail investors saw a net inflow of 8.79 million yuan [3].